Neurotensin receptor 1 is expressed in gastrointestinal stromal tumors but not in interstitial cells of Cajal

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Gromova, Petra ^a   Rubin, Brian P ^b   Thys, An ^a   Erneux, Christophe ^a   Vanderwinden, Jean Marie ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NEUROMEDIN N; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR; UNCLASSIFIED DRUG; NEUROTENSIN TYPE 1 RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER MORPHOLOGY; CARCINOGENESIS; CELL HYPERPLASIA; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION REGULATION; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERSTITIAL CELL OF CAJAL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ANTRUM; TISSUE MICROARRAY; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TUMOR LOCALIZATION; TUMOR MODEL; UPREGULATION; ANIMAL; DISEASE MODEL; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALIA; MURINAE; MUS;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERSTITIAL CELLS OF CAJAL; MALE; MICE; MICE, TRANSGENIC; MICROARRAY ANALYSIS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, NEUROTENSIN;

EID: 79951985201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014710     Document Type: Article

References (40)

1. Kitamura Y, (2008) Gastrointestinal stromal tumors: past, present, and future. J Gastroenterol 43: 499-508.
2. Liegl-Atzwanger B, Fletcher JA, Fletcher CD, (2010) Gastrointestinal stromal tumors. Virchows Arch 456: 111-127.
3. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, et al. (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 10: 81-89.
4. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, et al. (2004) KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28: 889-894.
5. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349.
6. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, et al. (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23: 5357-5364.
7. Blay P, Astudillo A, Buesa JM, Campo E, Abad M, et al. (2004) Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 10: 4089-4095.
8. Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, et al. (2004) Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 64: 5127-5131.
9. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, et al. (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165: 107-113.
10. Parkkila S, Lasota J, Fletcher JA, Ou WB, Kivela AJ, et al. (2010) Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol 23: 743-750.
11. Gomez-Pinilla PJ, Gibbons SJ, Bardsley MR, Lorincz A, Pozo MJ, et al. (2009) Ano1 is a selective marker of interstitial cells of Cajal in the human and mouse gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 296: G1370-G1381.
12. Chen H, Ordog T, Chen J, Young DL, Bardsley MR, et al. (2007) Differential gene expression in functional classes of interstitial cells of Cajal in murine small intestine. Physiol Genomics 31: 492-509.
13. Rubin BP, Antonescu CR, Scott-Browne JP, Comstock ML, Gu Y, et al. (2005) A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 65: 6631-6639.
14. Gromova P, Ralea S, Lefort A, Libert F, Rubin BP, et al. (2009) Kit K641E oncogene up-regulates Sprouty homolog 4 and trophoblast glycoprotein in interstitial cells of Cajal in a murine model of gastrointestinal stromal tumours. J Cell Mol Med 13: 1536-1548.
15. Garcia-Garayoa E, Blauenstein P, Blanc A, Maes V, Tourwe D, et al. (2009) A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur J Nucl Med Mol Imaging 36: 37-47.
16. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J, (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19.
17. Miettinen M, Lasota J, (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70-83.
18. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, et al. (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5 (Suppl 2): S1-29.
19. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, et al. (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054-5058.
20. Toy-Miou-Leong M, Cortes CL, Beaudet A, Rostene W, Forgez P, (2004) Receptor trafficking via the perinuclear recycling compartment accompanied by cell division is necessary for permanent neurotensin cell sensitization and leads to chronic mitogen-activated protein kinase activation. J Biol Chem 279: 12636-12646.
21. Toy-Miou-Leong M, Bachelet CM, Pelaprat D, Rostene W, Forgez P, (2004) NT agonist regulates expression of nuclear high-affinity neurotensin receptors. J Histochem Cytochem 52: 335-345.
22. Souaze F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, et al. (2006) Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res 66: 6243-6249.
23. Souaze F, Viardot-Foucault V, Roullet N, Toy-Miou-Leong M, Gompel A, et al. (2006) Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas. Carcinogenesis 27: 708-716.
24. Blackburn AM, Bloom SR, (1979) A radioimmunoassay for neurotensin in human plasma. J Endocrinol 83: 175-181.
25. Shaw C, Buchanan KD, (1983) Intact neurotensin (NT) in human plasma: response to oral feeding. Regul Pept 7: 145-153.
26. Dong Z, Wang X, Zhao Q, Townsend CM Jr., Evers BM, (1998) DNA methylation contributes to expression of the human neurotensin/neuromedin N gene. Am J Physiol 274: G535-G543.
27. Theodorsson-Norheim E, Oberg K, Rosell S, Bostrom H, (1983) Neurotensinlike immunoreactivity in plasma and tumor tissue from patients with endocrine tumors of the pancreas and gut. Gastroenterology 85: 881-889.
28. Meggiato T, Ferrara C, Tessari G, Plebani M, De Paoli M, et al. (1996) Serum neurotensin in human pancreatic cancer. Tumori 82: 592-595.
29. Carraway RE, Plona AM, (2006) Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides 27: 2445-2460.
30. Evers BM, (2006) Neurotensin and growth of normal and neoplastic tissues. Peptides 27: 2424-2433.
31. Reubi JC, Waser B, Schaer JC, Laissue JA, (1999) Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int J Cancer 82: 213-218.
32. Dupouy S, Viardot-Foucault V, Alifano M, Souaze F, Plu-Bureau, et al. (2009) The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS ONE 4: e4223.
33. Van den Abbeele AD, Badawi RD, (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38 (Suppl 5): S60-5.
34. Jager PL, Gietema JA, van der Graaf WT, (2004) Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 25: 433-438.
35. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, et al. (2009) Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 27: 439-445.
36. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den AA, et al. (2005) Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 235: 892-898.
37. Buchegger F, Bonvin F, Kosinski M, Schaffland AO, Prior J, et al. (2003) Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 44: 1649-1654.
38. Arango-Rodriguez ML, Navarro-Quiroga I, Gonzalez-Barrios JA, Martinez-Arguelles DB, Bannon MJ, et al. (2006) Biophysical characteristics of neurotensin polyplex for in vitro and in vivo gene transfection. Biochim Biophys Acta 1760: 1009-1020.
39. Gonzalez-Barrios JA, Lindahl M, Bannon MJ, Anaya-Martinez V, Flores G, et al. (2006) Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol Ther 14: 857-865.
40. Martinez-Fong D, Navarro-Quiroga I, (2000) Synthesis of a non-viral vector for gene transfer via the high-affinity neurotensin receptor. Brain Res Brain Res Protoc 6: 13-24.